Business Context and Reporting Period
This Form 8-K, filed on January 12, 2015, reports a material definitive agreement entered into by AmerisourceBergen Corporation (the "Company") on January 11, 2015. The Company, through its wholly-owned subsidiary Roscoe Acquisition Corp., has agreed to acquire MWI Veterinary Supply, Inc. ("MWI") via a cash tender offer followed by a merger.
Key Financial Metrics and Transaction Terms
- Purchase Price: $190.00 per share in cash, net to the seller, without interest, less applicable withholding taxes.
- Financing: Bank of America, N.A. has committed to a $2,150,000,000 senior unsecured bridge term loan facility to fund the transaction.
- Termination Fee: MWI is required to pay a termination fee of $76,000,000 if it terminates the agreement to accept a "Superior Proposal."
- Equity Treatment: Outstanding stock options will become fully vested and exercisable; unvested restricted stock awards will become fully vested. Options and shares will be converted into cash based on the merger consideration.
Note: This filing does not provide historical revenue, profit, cash flow, or margin data for either company.
Material Changes and Conditions
The primary material change is the initiation of a cash tender offer for all outstanding shares of MWI. The transaction is subject to several conditions:
- Tender Threshold: Valid tender of shares representing at least a majority of MWI's outstanding shares on a fully diluted basis.
- Regulatory Approval: Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Financing Conditions: The debt commitment is subject to customary conditions, including the absence of a "material adverse effect" on MWI and the solvency of the Company post-transaction.
- Structure: Following the tender offer, Merger Sub will merge with MWI under Section 251(h) of the Delaware General Corporation Law, requiring no stockholder vote.
Outlook, Risks, and Management Commentary
Management has issued forward-looking statements regarding the anticipated benefits of the transaction and the ability to satisfy closing conditions. Key risks and contingencies include:
- Transaction Uncertainty: Risks associated with the timing of the offer and merger, and the possibility that conditions may not be satisfied or waived.
- Operational Disruption: Potential disruption to the businesses of both companies and difficulties in maintaining relationships with employees, suppliers, and partners during the pendency of the transaction.
- Superior Proposals: MWI retains the right to solicit alternative proposals if they constitute a "Superior Proposal" (more favorable financially and reasonably capable of completion), which could trigger the termination fee.
Investor Verification Checklist
- Verify the final tender offer statement and MWI's Solicitation/Recommendation Statement (Schedule 14D-9) once filed with the SEC.
- Confirm the satisfaction of the Hart-Scott-Rodino antitrust waiting period.
- Monitor the percentage of shares tendered to ensure the majority ownership threshold is met.
- Review the full text of the Merger Agreement (Exhibit 2.1) and Debt Commitment Letter (Exhibit 10.1) for detailed representations, warranties, and covenants.
- Assess the potential for a "Superior Proposal" and the associated $76 million termination fee obligation.